These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 9705383)
21. A comparison of anticryptosporidial activity of paromomycin with that of other aminoglycosides and azithromycin in immunosuppressed rats. Rehg JE J Infect Dis; 1994 Oct; 170(4):934-8. PubMed ID: 7930738 [TBL] [Abstract][Full Text] [Related]
22. Development of particulate drug formulation against C. parvum: Formulation, characterization and in vivo efficacy. Blanco-García E; Guerrero-Callejas F; Blanco-Méndez J; Gómez-Couso H; Luzardo-Álvarez A Eur J Pharm Sci; 2016 Sep; 92():74-85. PubMed ID: 27381880 [TBL] [Abstract][Full Text] [Related]
23. Dynamics of gut mucosal and systemic Th1/Th2 cytokine responses in interferon-gamma and interleukin-12p40 knock out mice during primary and challenge Cryptosporidium parvum infection. Tessema TS; Schwamb B; Lochner M; Förster I; Jakobi V; Petry F Immunobiology; 2009; 214(6):454-66. PubMed ID: 19155092 [TBL] [Abstract][Full Text] [Related]
24. Efficacy of mangiferin against Cryptosporidium parvum in a neonatal mouse model. Perrucci S; Fichi G; Buggiani C; Rossi G; Flamini G Parasitol Res; 2006 Jul; 99(2):184-8. PubMed ID: 16547730 [TBL] [Abstract][Full Text] [Related]
25. A Novel Piperazine-Based Drug Lead for Cryptosporidiosis from the Medicines for Malaria Venture Open-Access Malaria Box. Jumani RS; Bessoff K; Love MS; Miller P; Stebbins EE; Teixeira JE; Campbell MA; Meyers MJ; Zambriski JA; Nunez V; Woods AK; McNamara CW; Huston CD Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29339392 [TBL] [Abstract][Full Text] [Related]
26. Chemoprophylaxis of Cryptosporidium parvum infection with paromomycin in kids and immunological study. Mancassola R; Reperant JM; Naciri M; Chartier C Antimicrob Agents Chemother; 1995 Jan; 39(1):75-8. PubMed ID: 7695333 [TBL] [Abstract][Full Text] [Related]
27. Adoptive transfer of protective immunity from Cryptosporidium parvum-infected interferon-gamma and interleukin-12-deficient mice to naive recipients. Tessema TS; Dauber E; Petry F Vaccine; 2009 Nov; 27(47):6575-81. PubMed ID: 19717136 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of curative anticryptosporidial activity of paromomycin in a dexamethasone-treated rat model. Verdon R; Polianski J; Gaudebout C; Marche C; Garry L; Pocidalo JJ Antimicrob Agents Chemother; 1994 Jul; 38(7):1681-2. PubMed ID: 7979310 [TBL] [Abstract][Full Text] [Related]
29. Infectivity of a Cryptosporidium parvum isolate of cervine origin for healthy adults and interferon-gamma knockout mice. Okhuysen PC; Rich SM; Chappell CL; Grimes KA; Widmer G; Feng X; Tzipori S J Infect Dis; 2002 May; 185(9):1320-5. PubMed ID: 12001050 [TBL] [Abstract][Full Text] [Related]
30. Assessment of Cryptosporidium parvum infection in immunocompetent and immunocompromised mice and its role in triggering intestinal dysplasia. Abdou AG; Harba NM; Afifi AF; Elnaidany NF Int J Infect Dis; 2013 Aug; 17(8):e593-600. PubMed ID: 23291034 [TBL] [Abstract][Full Text] [Related]
31. Liver and bile duct pathology following Cryptosporidium parvum infection of immunodeficient mice. Stephens J; Cosyns M; Jones M; Hayward A Hepatology; 1999 Jul; 30(1):27-35. PubMed ID: 10385635 [TBL] [Abstract][Full Text] [Related]
32. [Efficacy of paromomycin sulfate (Humagel) in an AIDS infected patient with intestinal cryptosporidiosis]. Hammel P; Rogeaux O; Diouf ML; Gouyon B; Ruszniewski P; Bernades P Gastroenterol Clin Biol; 1992; 16(12):1010-1. PubMed ID: 1493891 [No Abstract] [Full Text] [Related]
33. Comparative efficacy evaluation of dicationic carbazole compounds, nitazoxanide, and paromomycin against Cryptosporidium parvum infections in a neonatal mouse model. Blagburn BL; Drain KL; Land TM; Kinard RG; Moore PH; Lindsay DS; Patrick DA; Boykin DW; Tidwell RR Antimicrob Agents Chemother; 1998 Nov; 42(11):2877-82. PubMed ID: 9797219 [TBL] [Abstract][Full Text] [Related]